U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C23H15ClF2N4O3
Molecular Weight 468.84
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BMS-794833

SMILES

NC1=C(Cl)C(OC2=C(F)C=C(NC(=O)C3=CNC=C(C3=O)C4=CC=C(F)C=C4)C=C2)=CC=N1

InChI

InChIKey=PDYXPCKITKHFOZ-UHFFFAOYSA-N
InChI=1S/C23H15ClF2N4O3/c24-20-19(7-8-29-22(20)27)33-18-6-5-14(9-17(18)26)30-23(32)16-11-28-10-15(21(16)31)12-1-3-13(25)4-2-12/h1-11H,(H2,27,29)(H,28,31)(H,30,32)

HIDE SMILES / InChI
Molecular Formula C23H15ClF2N4O3
Molecular Weight 468.84
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including http://www.ejcancersupplements.com/article/S1359-6349(10)71801-2/abstract | http://www.ejcancersupplements.com/article/S1359-6349(10)71811-5/abstract | http://adisinsight.springer.com/drugs/800022289 | http://adisinsight.springer.com/drugs/800046444

BMS-794833 (N-(4-(2-Amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-5-(4- fluorophenyl)-4-oxo-l,4-dihydropyridine-3-carboxamide) is an inhibitor of Met, VEGFR2, Ron, Axl and Flt-3 kinases. BMS-794833 demonstrated dose-dependent tumor growth inhibition following oral administration in xenograft models. In cell culture, BMS-794833 inhibited the proliferation of human tumor cell lines containing constitutively activated Met receptor. BMS-794833 is an active moety of pro-drug BMS-817378. Bristol-Myers Squibb and Simcere Pharmaceutical Group are developing BMS-817378 for treatment of cancer.

CNS Activity

CNS Active
3897
Curator's Comment: Brain penetration of BMS-794833 is unknown, however BMS-794833 demonstrates antitumor activity against U87 glioblastoma xenografts

Originator

Bristol-Myers Squibb
145
Curator's Comment: # Bristol-Myers Squibb

Approval Year

Unknown
127998
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8146
 1.7 nM [IC50]
Inhibitor
8146
 15.0 nM [IC50]
Macrophage-stimulating protein receptor
4
Target ID: CHEMBL2689
Sources: DOI: 10.1016/S1359-6349(10)71801-2
Inhibitor
8146
 3.0 nM [IC50]
Tyrosine-protein kinase receptor UFO
13
Target ID: CHEMBL4895
Sources: DOI: 10.1016/S1359-6349(10)71801-2
Inhibitor
8146
 3.0 nM [IC50]
Tyrosine-protein kinase receptor FLT3
43
Target ID: CHEMBL1974
Sources: DOI: 10.1016/S1359-6349(10)71801-2
Inhibitor
8146
 3.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Phase I
422
Unknown

Approved Use

Unknown
Patents

Patents

WO2009094417A1
1

Sample Use Guides

In Vivo Use Guide
antitumor activity of BMS-794833 dosed orally once daily for 14 days 6.25 mpk (mg/kg), 12.5 mpk, and 25 mpk was tested against U87 glioblastoma xenografts.
Route of Administration: Oral
In Vitro Use Guide
Sources: DOI: 10.1016/S1359-6349(10)71801-2 https://google.com/patents/WO2009094417A1
Curator's Comment: BMS-794833 inhibited the proliferation of human tumor cell lines containing constitutively activated Met receptor (GTL-16 gastric carcinoma)
Unknown
Substance Class Chemical
Created
by admin
on Sun Dec 18 22:22:11 UTC 2022
Edited
by admin
on Sun Dec 18 22:22:11 UTC 2022
Record UNII
SAY8KVM4HU
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BMS-794833
Code English
3-PYRIDINECARBOXAMIDE, N-(4-((2-AMINO-3-CHLORO-4-PYRIDINYL)OXY)-3-FLUOROPHENYL)-5-(4-FLUOROPHENYL)-1,4-DIHYDRO-4-OXO-
Systematic Name English
Code System Code Type Description
CAS
1174046-72-0
Created by admin on Sun Dec 18 22:22:11 UTC 2022 , Edited by admin on Sun Dec 18 22:22:11 UTC 2022
PRIMARY
FDA UNII
SAY8KVM4HU
Created by admin on Sun Dec 18 22:22:11 UTC 2022 , Edited by admin on Sun Dec 18 22:22:11 UTC 2022
PRIMARY
PUBCHEM
44155856
Created by admin on Sun Dec 18 22:22:11 UTC 2022 , Edited by admin on Sun Dec 18 22:22:11 UTC 2022
PRIMARY
EPA CompTox
DTXSID30657662
Created by admin on Sun Dec 18 22:22:11 UTC 2022 , Edited by admin on Sun Dec 18 22:22:11 UTC 2022
PRIMARY
Related Record Type Details
RECEPTOR-TYPE TYROSINE-PROTEIN KINASE FLT3
TARGET -> INHIBITOR
IC50
TYROSINE-PROTEIN KINASE MER
TARGET -> INHIBITOR
IC50
TYROSINE-PROTEIN KINASE RECEPTOR UFO
TARGET -> INHIBITOR
IC50
TYROSINE-PROTEIN KINASE RECEPTOR TYRO3
TARGET -> INHIBITOR
IC50
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966